Robotimize expands ACE exoskeleton rollout across Northern Malaysia

Robotimize Group introduced three RoboCT exoskeletons from its ACE strategic partnerships portfolio to healthcare providers and care communities across Northern Malaysia on September 14, 2026. The rollout spans private centres, rehabilitation institutions and care centres as the company broadens beyond the Klang Valley and pushes more than one device into regional care settings.

Why it matters: - Robotimize is widening its rehabilitation technology footprint in Northern Malaysia, a region the company has historically served less than the Klang Valley. - The rollout puts multiple exoskeleton options in front of clinicians, caregivers and residents, which matters because mobility and recovery needs differ across paediatric, adult and elderly care. - The introduction is part of Robotimize’s broader effort to show how external innovation can fit into real care pathways, not just single-device demonstrations.

What happened: - Robotimize Group introduced UGO, KidGo and GoGo, three exoskeletons from RoboCT, to healthcare providers and care communities across Northern Malaysia. - The company explored the ACE™ portfolio in private centres, rehabilitation institutions and care centres. - The introduction took place on September 14, 2026, in Malaysia. - Kerry Guo, Founder and CEO of Robotimize Group, said Northern Malaysia has its own healthcare landscape and the company wants its technology to be useful within it.

The details: - The ACE™ strategic partnerships portfolio sits alongside VivantePlexus™, Robotimize’s integrated rehabilitation technology ecosystem. - The ACE™ portfolio is designed to bring validated technologies from partnering innovators to healthcare providers and care communities across the region. - UGO, KidGo and GoGo are three exoskeletons developed by RoboCT within that portfolio. - The company said introducing all three devices together gave the team a chance to show the breadth of the range. - The exploration let clinicians and caregivers assess how exoskeleton technology might fit alongside existing rehabilitation programmes. - The use cases ranged from clinician-led therapy in rehabilitation institutions to everyday mobility support in private care centres. - The settings also covered paediatric gait training, recovery from neurological conditions and older residents aiming to stay mobile and independent. - Even Koh, Group General Manager of Robotimize Group, said every setting had different needs and the range of exoskeletons allowed the team to address each one directly. - Robotimize said the value of the technology depends on training, support and everyday familiarity, not on the device alone. - The company said the portfolio model is built to match the right external innovation to the right patient. - Robotimize said introducing a range of exoskeletons together gives healthcare providers and care communities a fuller picture of what a partnership with the company can look like over time.

Between the lines: - The regional rollout suggests Robotimize is moving from product introduction toward ecosystem building. - Showing multiple devices at once may help the company position ACE™ as a platform for different care needs instead of a single flagship product. - The focus on training and support signals that adoption will depend as much on implementation as on hardware.

What's next: - Robotimize said it will continue introducing technologies from its ACE™ strategic partnerships portfolio to healthcare providers and care communities across the region. - The company is working with institutions that are exploring how external innovation can be built into their rehabilitation approach across paediatric to elderly care. - Product availability, indications and use remain subject to applicable regulatory approvals and local clinical requirements. - More information is available in the company’s announcement.